Anlon Healthcare Limited (AHCL)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 1 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹14.61

🎯 Key Takeaways

Anlon Healthcare Limited is in a rapid growth phase driven by strategic acquisitions and expansion into new therapeutic segments. The company completed its first major acquisition in Q1FY27, gaining control of Remember India Health Links to enter finished dosage formulations, and is actively building an integrated pharmaceutical platform.
⚠️ Integration risk from rapid acquisitions, including cultural and operational alignment challenges in newly acquired businesses.

Market Cap

₹710

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About AHCL 📊 Interactive Charts

📖 The Story

Anlon Healthcare Limited is in a rapid growth phase driven by strategic acquisitions and expansion into new therapeutic segments. The company completed its first major acquisition in Q1FY27, gaining control of Remember India Health Links to enter finished dosage formulations, and is actively building an integrated pharmaceutical platform. Management is targeting 30% revenue CAGR over three years while maintaining healthy EBITDA margins of 25%-30%. This marks a clear shift from prior periods of volatility to a deliberate scaling strategy.

📰 What's Happening

In Q1FY27, Anlon Healthcare reported consolidated revenue of ₹87.62 Crore, up 163.02% YoY, with PAT at ₹8.28 Crore (+133.13% YoY) and EBITDA at ₹15.65 Crore (+150.14% YoY). The company completed the acquisition of a 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 Crore, gaining entry into finished dosage formulations. Subsequently, the board approved the acquisition of 32.52% in Apiqo Organics and 43.33% in Bizotic LifeScience via non-cash equity issuance, making them wholly owned subsidiaries. Additionally, two new subsidiaries — Anlon Medicare and Anlon Biologics — were incorporated to expand into surgical implants and biologics manufacturing, with renaming of Remember India Health Links pending MCA approval.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY26
Revenue	51
Operating Profit	15
OPM %	30.1%
Net Profit	11
EPS	₹2.33

The company's financial trajectory shows a sharp inflection from prior quarter underperformance to strong growth in Q1FY27, with revenue and profitability expanding significantly. This turnaround is directly linked to the acquisition of Remember India Health Links and the subsequent strategic realignment. Management attributes the improved margins and growth to operational synergies and integration of new businesses, with expectations of sustained 30% revenue CAGR over three years. The shift reflects a deliberate move from legacy challenges to scalable, margin-accretive expansion.

🔮 Management Outlook & What's Next

Management has explicitly stated confidence in achieving approximately 30% revenue CAGR over the next three years while maintaining EBITDA margins in the range of 25%–30%. This guidance is tied to the successful integration of newly acquired businesses and expansion into high-growth segments like finished dosage formulations, surgical implants, and biologics. The company is focused on building an integrated pharmaceutical platform through disciplined capital allocation and non-cash equity-based acquisitions.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	2025-2026
Equity Capital	53
Reserves	177
Borrowings	44
Total Liabilities	119
Fixed Assets	58
Investments	0
Total Assets	374

The balance sheet indicates a strengthening financial position with equity of ₹53 Crore and reserves of ₹177 Crore, supporting growth initiatives. Borrowings of ₹44 Crore are modest relative to asset base of ₹374 Crore, suggesting limited leverage. The company is funding expansion primarily through internal resources and equity instruments, including non-cash consideration for acquisitions, reflecting a conservative capital structure and prudent capital allocation strategy.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Integration risk from rapid acquisitions, including cultural and operational alignment challenges in newly acquired businesses. 2. Execution risk in achieving stated 30% revenue CAGR and margin targets, particularly in new segments like biologics and surgical implants. 3. Regulatory and compliance risks associated with setting up new subsidiaries and manufacturing facilities. 4. Market concentration risk, as growth is currently driven by a single quarter of strong performance following acquisition completion.

📋 Recent Filings

🧠 Analyst's Read

Anlon Healthcare is transitioning from a period of financial stress to an aggressive expansion phase backed by strategic acquisitions and clear growth targets. The next few quarters will be critical in validating management's ability to integrate new businesses and deliver on growth and margin commitments. Investors should monitor execution updates, integration progress, and capital allocation efficiency as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on AHCL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AHCL files new disclosures

Track AHCL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AHCL — Free

Free account · 2 AI queries/day